Anthem Biosciences Limited has updated the Exchange about Key Performance Indicators for the financial year ended March 31, 2026

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.3%1-day move

₹780.00

prior close

₹801.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2+1.0+0.8+0.4-1.3-0.5-2.2-1.3-3.0-3.8+0.0-1.7+1.2—

Up moveDown movePending

AI summary

Anthem Biosciences filed its annual KPI disclosure with stock exchanges, verified by statutory auditors K.P. Rao & Co. The company reported total revenue of ₹21,243.33 million for FY 2026, up 15.17% year-on-year. EBITDA stood at ₹8,971.69 million with a strong margin of 47.07%, while PAT reached ₹5,917.92 million with a 25.95% margin. Revenue is heavily weighted toward CRDMO services (83%) versus Specialty Ingredients (17%). The company holds net cash of ₹13,743.54 million, translating to a comfortable Net Cash/EBITDA ratio of 1.53x. Operational metrics show 2,282 employees including 1,117 scientific staff and 32 PhDs.

Likely market impact

Strong KPI numbers reflect a healthy contract research and manufacturing business with improving profitability and a cash-rich balance sheet, which is positive for shareholders.